

Seminario

# GIORNATA REGIONALE DELLA SICUREZZA E QUALITÀ DELLE CURE 2019



RETE CURE SICURE FVG



REGIONE AUTONOMA FRIULI VENEZIA GIULIA



PROFESSORATO  
SPERIMENTALE  
IN CURA E ASSISTENZA

azienda sanitaria universitaria  
integrata di Udine



REGIONE AUTONOMA  
FRIULI VENEZIA GIULIA

# Le linee guida e le raccomandazioni

**P. Iannone**

*10.12.2019*


**Centro Nazionale Eccellenza  
Clinica Qualità e Sicurezza delle Cure**



# Thrombolytic Therapy in Acute Myocardial Infarction

Cumulative Meta-Analysis

Textbook/Review Recommendations





## THE SUNDAY TIMES

5 FEBRUARY 1995

### Hundreds killed by doctors relying on outdated manuals

Routine	Common	Rare/Never	Experimental	Not Mentioned
				21
				5
			1	9
			1	2
			2	8
				6
				8
	1			12
	1		8	4
	1		7	3
5	2		2	1
15	8			1
6	1			





**Figure 2. The number of published trials, 1950 to 2007.** CCTR is the Cochrane Controlled Trials Registry; Haynes filter uses the “narrow” version of the Therapy filter in PubMed:ClinicalQueries; see Text S1.  
doi:10.1371/journal.pmed.1000326.g002

**Citation:** Bastian H, Glasziou P, Chalmers I (2010) Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up? PLoS Med 7(9): e1000326. doi:10.1371/journal.pmed.1000326

**Published** September 21, 2010

**OPEN ACCESS** Freely available online

PLoS MEDICINE

Policy Forum

# Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up?

**Hilda Bastian<sup>1\*</sup>, Paul Glasziou<sup>2</sup>, Iain Chalmers<sup>3</sup>**

**1** German Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, **2** Centre for Research in Evidence-Based Practice, Faculty of Health Sciences, Bond University, Gold Coast, Australia, **3** James Lind Library, James Lind Initiative, Oxford, United Kingdom



# 1. Clinical questions and information needs

Jeremy C Wyatt DM FRCP

*J R Soc Med* 2000;93:168-171





Figure 1 Structure of Knowledge for the Clinician

Estimated Avoidable Costs by Lever (US\$Bn, 2012)



Source: Avoidable costs in healthcare study

Avoidable Costs in U.S. Healthcare: The \$200 Billion Opportunity from Using Medicines More Responsibly. Report by the IMS Institute for Healthcare Informatics.







**The Rational Clinical Examination** 

# Evidence-Based Medicine

A New Approach to Teaching the Practice of Medicine

Evidence-Based Medicine Working Group

JAMA, November 4, 1992—Vol 268, No. 17

the committee believes are defining characteristics. The new definition is as follows: **Clinical practice guidelines are statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options.**

To be *trustworthy*, guidelines should



scelta

*Guidelines, not tramlines*

Institute of Medicine, 2011



Consensus based

consensus



(Strength of)



recommendation

Quality of evidence



Certainty  
(Level of evidence)

Strength  
of recommendations



Graded recommendations





HULTON/GETTY

Parachutes reduce the risk of injury after gravitational challenge, but their effectiveness has not been proved with randomised controlled trials

Sometimes trials are unethical or impossible yet some treatments are quite effective


---

# Grading quality of evidence and strength of recommendations

Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) Working Group

Clinical guidelines are only as good as the evidence and judgments they are based on. The GRADE approach aims to make it easier for users to assess the judgments behind recommendations

*BMJ* 2004;328:1490-4



# Qualità delle prove

Fino a che punto possiamo credere che le stime di effetto di un intervento siano vere?

# Forza delle raccomandazioni

Quanto siamo certi che  
l'aderenza ad una determinata  
raccomandazione porti ad un  
beneficio superiore ai possibili  
danni

2008;336;924-926 *BMJ*  
2008;336;995-998 *BMJ*  
2008;336;1049-1051 *BMJ*

**RATING QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS**

## **GRADE: an emerging consensus on rating quality of evidence and strength of recommendations**

Guidelines are inconsistent in how they rate the quality of evidence and the strength of recommendations. This article explores the advantages of the GRADE system, which is increasingly being adopted by organisations worldwide

Guideline developers around the world are inconsistent in how they rate quality of evidence and grade strength of recommendations. As a result, guideline users face challenges in understanding the messages that grading systems try to communicate. Since 2006 the *BMJ* has requested in its "Instructions to Authors" on [bmj.com](http://bmj.com) that authors should preferably use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for grading evidence when submitting a clinical guidelines article.

Gordon H Guyatt professor,  
Department of Clinical  
Epidemiology and Biostatistics,  
McMaster University, Hamilton,  
ON, Canada L8N 3Z5

Andrew D Oxman researcher,  
Norwegian Knowledge Centre for  
the Health Services, PO Box 7004,  
St Olavs Pass, 0130 Oslo, Norway

Gunn E Vist researcher,  
Norwegian Knowledge Centre for  
the Health Services, PO Box 7004,

advantages and disadvantages but also by their confidence in these estimates. The cartoon depicting the weather forecaster's uncertainty captures the difference between an assessment of the likelihood of an outcome and the confidence in that assessment (figure). The usefulness of an estimate of the magnitude of intervention effects depends on our confidence in that estimate.

Expert clinicians and organisations offering recommendations to the clinical community have often erred as a result of not taking sufficient account of the quality

[www.gradeworkinggroup.org](http://www.gradeworkinggroup.org)






Fig. 1. Schematic view of GRADE's process for developing recommendations. *Abbreviation:* RCT, randomized controlled trials.

# VALUTAZIONE EtD

- 1 Priorità del problema
- 2 Effetti desiderati
- 3 Effetti indesiderati
- 4 Certezza delle prove
- 5 Valori
- 6 Bilancio dell'effetto

- 7 Risorse richieste
- 8 Certezza delle risorse
- 9 Costo-efficacia
- 10 Equità
- 11 Accettabilità
- 12 Fattibilità

## Box 4. Criteri considerati nel GRADE EtD framework

**Problema:** Il problema è una priorità? (già valutato nella fase iniziale di sviluppo della LG, quindi si può omettere dalla descrizione del framework EtD)

**Benefici attesi:** Quanto sono importanti i benefici attesi?

**Effetti indesiderati:** Quanto sono importanti gli effetti indesiderati?

**Qualità globale delle prove:** Fino a che punto si può confidare nel fatto che la stima di beneficio/danno possa essere usata a favore/contro il raccomandare l'uso dell'intervento proposto?

**Valori:** Vi è incertezza o variabilità rispetto al valore che le persone attribuiscono agli outcome principali?

**Bilancio tra benefici e danni attribuibili all'intervento:** Il bilancio tra benefici ed effetti indesiderati favorisce l'intervento proposto o il confronto?

**Risorse richieste:**

- Quali sono i costi richiesti?
- Qual è il livello di evidenza relativo ai costi richiesti?
- L'analisi di costo-efficacia o di costo-utilità favorisce l'intervento proposto o il confronto?

**Equità:** Quale potrebbe essere l'impatto sull'equità?

**Accettabilità:** L'intervento proposto è accettabile da parte degli stakeholder?


**Fattibilità:** L'intervento proposto può essere implementato?

# LG differenziate per scopi

GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction

Pablo Alonso-Coello,<sup>1,2</sup> Holger J Schünemann,<sup>2,3</sup> Jenny Moberg,<sup>4</sup> Romina Brignardello-Petersen,<sup>2,5</sup> Elie A Akl,<sup>2,6</sup> Marina Davoli,<sup>7</sup> Shaun Treweek,<sup>8</sup> Reem A Mustafa,<sup>2,9</sup> Gabriel Rada,<sup>10,11,12</sup> Sarah Rosenbaum,<sup>4</sup> Angela Morelli,<sup>4</sup> Gordon H Guyatt,<sup>2,3</sup> Andrew D Oxman<sup>4</sup> the GRADE Working Group

Cite this as: *BMJ* 2016;**353**:i2016  
<http://dx.doi.org/10.1136/bmj.i2016>




# GRADE

## Per adattamento LG

### Il metodo GRADE-ADOLPMENT

Tradotto da: Schünemann et al. *Journal of Clinical Epidemiology* 2017 81, 101-110 DOI (10.1016/j.jclinepi.2016.09.009)

## Essenziale per la prospettiva nazionale SSN



producing a guideline is a very complex process involving technical skills (searching for primary evidence efficiently), value judgements (rating that evidence) and social aspects (managing discussion and achieving consensus within the guideline panel group)

Burgers JS, Bailey JV, Klazinga NS, et al. Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries. *Diabetes Care* 2002;25:1933–9.



**Figure 6** Estimated and projected age structure, UK population, mid-2010 and mid-2035







Figure 5 Number of chronic disorders by age group



Note: This figure shows how common it is to have significant long-term conditions in relation to age. Few people (fewer than 30 per cent) do not have at least one condition by the age of 60, and many people will have two or three.

# Il ruolo e l'attività del Centro Nazionale Eccellenza Clinica, Qualità e Sicurezza delle Cure in relazione al Sistema Nazionale Linee Guida

Milano 26 giugno 2019

Primiano Iannone


**Centro Nazionale Eccellenza  
Clinica Qualità e Sicurezza delle Cure**



## multimorbidità



**Fig 1 | Proportion of people with three index conditions who have each of other conditions. Morbidity data were not available for osteoarthritis or neuropathic pain; “painful condition” data shown are defined by receipt of four or more prescriptions for non-over the counter analgesics in previous 12 months**




**Fig 2 | Potentially serious drug-drug interactions between drugs recommended by clinical guidelines for three index conditions and drugs recommended by each of other 11 other guidelines**

**Allineamento ISS allo  
standard di riferimento  
internazionale per LG WHO,  
NICE, SIGN...**



Offrire LG di alta qualità metodologica rilevanti e valide per le finalità dell' SSN

 > Archivio per categoria "LG internazionali"

Archivi categoria: *LG internazionali*

### LG internazionali

In questa sezione sono riportate le LG internazionali selezionate e indicate dal CNEC come punto di riferimento per i produttori di LG SNLG per l'adattamento delle stesse al contesto nazionale. Tali LG sono selezionate dal CNEC attraverso un processo di ricognizione della letteratura biomedica e la sorveglianza attiva dei documenti pubblicati dagli enti, dalle società scientifiche e dalle agenzie internazionali che producono LG.

I criteri adottati per la selezione delle LG sono i seguenti:

- corretta gestione del conflitto di interessi
- buona/elevata qualità metodologica
- composizione multidisciplinare/multiprofessionale del panel di esperti della LG
- revisione della LG condotta da referee esterni indipendenti.

**Disclaimer.** Le LG internazionali non sono assimilabili alle LG SNLG ai fini della L. 24/2017 in quanto non elaborate dai soggetti ex art 5 comma 1. Inoltre, pur provenendo da fonti di alto valore scientifico, tali LG possono, tuttavia, contenere raccomandazioni e consigli clinici non direttamente applicabili al contesto sanitario italiano e/o non compatibili con le disposizioni di legge, i regolamenti degli ordini professionali o i provvedimenti delle agenzie regolatorie italiane. Pertanto, i lettori sono invitati a considerare attentamente questa eventualità nel processo di adattamento delle raccomandazioni al contesto nazionale.

# International Guidelines Evaluation Screening Tool (IGEST) Content Validity Questionnaire

**CNEC** Centro Nazionale  
per l'Eccellenza Clinica, la Qualità e la Sicurezza delle Cure



Content Validity Questionnaire

*Excellence, Quality and Safety*



**al Practice Guidelines in the SNLG-ISS**

ary 2019

determine whether to include international Clinical  
database held by the SNLG-ISS. The 13 criteria,  
screening of CPGs. In addition, it is recommended  
adopting the tools suggested in the specific sections



# Clinical practice guideline

the committee believes are defining characteristics. The new definition is as follows: **Clinical practice guidelines are statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options.**  
*To be trustworthy, guidelines should*

# Clinical pathway

Schedules of medical and nursing procedures, including diagnostic tests, medications, and consultations designed to effect an efficient, coordinated program of treatment. (From Mosby's Medical, Nursing and Allied Health Dictionary, 4th ed)

Year introduced: 1996

CORRESPONDENCE

Open Access


## What is a clinical pathway? Refinement of an operational definition to identify clinical pathway studies for a Cochrane systematic review




Adegboyega K. Lawal<sup>1\*</sup>, Thomas Rotter<sup>1</sup>, Leigh Kinsman<sup>2</sup>, Andreas Machotta<sup>3</sup>, Ulrich Ronellenfitsch<sup>4</sup>, Shannon D. Scott<sup>5</sup>, Donna Goodridge<sup>6</sup>, Christopher Plishka<sup>1</sup> and Gary Groot<sup>6</sup>

- Pianificazione strutturata e multidisciplinare di un percorso clinico (-assistenziale)
- **Finalizzato a trasferire linee guida o evidenze** in organizzazioni sanitarie locali (specifiche)
- Dettaglia i passaggi in un piano, algoritmo, percorso, protocollo o altro inventario di azioni da compiere in un arco di tempo o sulla base di specifici criteri di progressione
- Inteso a standardizzare l'assistenza per una popolazione specifica

# LG come *safe harbour* ?



**80 % circa raccomandazioni deboli: quale valore medicolegale ?**



# Do we need more research or more translation of research findings ?

## RESEARCH METHODS & REPORTING



### How to estimate the health benefits of additional research and changing clinical practice

Karl Claxton,<sup>1,2</sup> Susan Griffin,<sup>1</sup> Hendrik Koffijberg,<sup>3,4</sup> Claire McKenna<sup>1</sup>

A simple extension of standard meta-analysis can provide quantitative estimates of the potential health benefits of further research and of implementing the findings of existing research, which can help inform research prioritisation and efforts to change clinical practice

Decisions about undertaking further research and at what point evidence should be implemented are important questions for research prioritisation and health policy. The results of standard meta-analysis can be extended to provide a quantitative assessment of the potential health benefits of gathering additional evidence and of implementing the findings in a way that consideration of statistical significance cannot.<sup>1</sup>

<sup>1</sup>Centre for Health Economics, University of York, York YO10 5DD, UK

<sup>2</sup>Department of Economics and Related Studies, University of York, York, UK

<sup>3</sup>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, The Netherlands


<sup>4</sup>Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands

Correspondence to: S Griffin  
susan.griffin@york.ac.uk


Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmj.h5987>)


Cite this as: *BMJ* 2015;351:h5987  
doi: 10.1136/bmj.h5987

Accepted: 13 October 2015



**Fig 4 |** Expected benefits of implementation (of streptokinase use following acute myocardial infarction) and potential benefits of further research, according to selected trials in example meta-analysis shown in figure 3. Solid line=95% credible interval; dashed line=90% credible interval

**Figure. The Interdependence of Evidence-Based Medicine and Shared  
Decision Making and the Need for Both as Part of Optimal Care**



An updated model for evidence based clinical decisions<sup>1</sup>

*Haynes RB et al. BMJ 2002;324:1350*



# HealthAffairs

---

At the Intersection of Health, Health Care and Policy

Cite this article as:  
John M. Eisenberg  
Globalize The Evidence, Localize The Decision: Evidence-Based Medicine  
And International Diversity  
*Health Affairs*, 21, no.3 (2002):166-168

doi: 10.1377/hlthaff.21.3.166

## Globalize The Evidence, Localize The Decision: Evidence-Based Medicine And International Diversity

The use of evidence is most successful when local differences are factored into the decision-making process, whether at the clinical, system, or policy level.

by **John M. Eisenberg**

# And so, what role for clinical guidelines ?

Advocacy, standard of care, balanced synthesis of best evidence available, identifying research & healthcare gaps

....

**guidelines (should) force us to scrutiny  
primary research literature in ways that  
we don't normally do**

Richard Horton, Editor of *The Lancet*